

Soo Ok Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2155387/publications.pdf>

Version: 2024-02-01

37
papers

1,813
citations

201674

27
h-index

265206

42
g-index

49
all docs

49
docs citations

49
times ranked

2997
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of IL-6/JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels. <i>Molecular Oncology</i> , 2018, 12, 269-286.	4.6	92
2	New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. <i>Journal of Molecular Cell Biology</i> , 2013, 5, 14-26.	3.3	91
3	RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. <i>Prostate</i> , 2004, 60, 303-309.	2.3	89
4	Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. <i>Prostate</i> , 2007, 67, 764-773.	2.3	85
5	Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. <i>Prostate</i> , 2004, 60, 178-186.	2.3	79
6	Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). <i>Prostate</i> , 2006, 66, 1070-1075.	2.3	78
7	New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells. <i>American Journal of Pathology</i> , 2013, 182, 460-473.	3.8	73
8	Androgen Receptor (AR) Pathophysiological Roles in Androgen Related Diseases in Skin, Metabolism Syndrome, Bone/Muscle and Neuron/Immune Systems: Lessons Learned from Mice Lacking AR in Specific Cells. <i>Nuclear Receptor Signaling</i> , 2013, 11, nrs.11001.	1.0	69
9	IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 6626-6638.	1.8	66
10	IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and dna repair associated molecules. <i>Oncotarget</i> , 2015, 6, 27651-27660.	1.8	62
11	Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. <i>Oncogene</i> , 2003, 22, 7981-7988.	5.9	61
12	Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway. <i>Oncotarget</i> , 2017, 8, 80506-80520.	1.8	59
13	Requirement for NF- κ B in interleukin-4-induced androgen receptor activation in prostate cancer cells. <i>Prostate</i> , 2005, 64, 160-167.	2.3	58
14	Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. <i>Hepatology</i> , 2013, 57, 1550-1563.	7.3	58
15	Androgen receptor (AR) in cardiovascular diseases. <i>Journal of Endocrinology</i> , 2016, 229, R1-R16.	2.6	58
16	Selenium Disrupts Estrogen Signaling by Altering Estrogen Receptor Expression and Ligand Binding in Human Breast Cancer Cells. <i>Cancer Research</i> , 2005, 65, 3487-3492.	0.9	55
17	IL-6 Mediates Macrophage Infiltration after Irradiation via Up-regulation of CCL2/CCL5 in Non-small Cell Lung Cancer. <i>Radiation Research</i> , 2017, 187, 50-59.	1.5	53
18	Increased Chemosensitivity via Targeting Testicular Nuclear Receptor 4 (TR4)-Oct4-Interleukin 1 Receptor Antagonist (IL1Ra) Axis in Prostate Cancer CD133+ Stem/Progenitor Cells to Battle Prostate Cancer. <i>Journal of Biological Chemistry</i> , 2013, 288, 16476-16483.	3.4	49

#	ARTICLE	IF	CITATIONS
19	Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer. <i>Cancer Science</i> , 2016, 107, 746-754.	3.9	46
20	A FASN-TGF- β 1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 55543-55554.	1.8	45
21	Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition. <i>Scientific Reports</i> , 2017, 7, 7958.	3.3	43
22	Suppressor role of androgen receptor in proliferation of prostate basal epithelial and progenitor cells. <i>Journal of Endocrinology</i> , 2012, 213, 173-182.	2.6	39
23	Concise Review: Androgen Receptor Differential Roles in Stem/Progenitor Cells Including Prostate, Embryonic, Stromal, and Hematopoietic Lineages. <i>Stem Cells</i> , 2014, 32, 2299-2308.	3.2	39
24	Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells. <i>Molecular Carcinogenesis</i> , 2016, 55, 2278-2290.	2.7	39
25	Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. <i>Prostate</i> , 2008, 68, 85-91.	2.3	38
26	Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells. <i>Prostate</i> , 2018, 78, 353-364.	2.3	36
27	Erk/MAP Kinase Signaling Pathway and Neuroendocrine Differentiation of Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 50-58.	1.1	23
28	Loss of androgen receptor promotes adipogenesis but suppresses osteogenesis in bone marrow stromal cells. <i>Stem Cell Research</i> , 2013, 11, 938-950.	0.7	21
29	In vitro -induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells. <i>Experimental Cell Research</i> , 2018, 364, 113-123.	2.6	20
30	Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2017, 18, 606-615.	3.4	17
31	Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. <i>Prostate</i> , 2007, 67, 1293-1300.	2.3	16
32	IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1471-1484.	2.5	14
33	Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer. <i>Prostate</i> , 2019, 79, 1414-1426.	2.3	13
34	Neuroendocrine differentiation contributes to radioresistance development and metastatic potential increase in non-small cell lung cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 1878-1890.	4.1	9
35	NF- κ B and TNF- α as individual key molecules associated with the cisplatin-resistance and radioresistance of lung cancer. <i>Experimental Cell Research</i> , 2019, 374, 181-188.	2.6	9
36	Increased infiltration of macrophages to radioresistant lung cancer cells contributes to the development of the additional resistance of tumor cells to the cytotoxic effects of NK cells. <i>International Journal of Oncology</i> , 2018, 53, 317-328.	3.3	4

#	ARTICLE	IF	CITATIONS
37	STAT3 and Transactivation of Steroid Hormone Receptors. <i>Vitamins and Hormones</i> , 2005, 70, 333-357.	1.7	3